FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely oncology and can be used in treatment of patients with colorectal cancer with multiple liver metastases. The first stage of treatment involves neoadjuvant oxalyplatine chemotherapy; in addition Tomudex is introduced in a dose 3 mg/m2 as a 24 hour continuous infusion. After termination of chemotherapy, biotherapy involves intra-arterial injection of Avastin in a dose 10 mg/kg of body weight within 2 hours, neoadjuvant intra-arterial chemotherapy and biotherapy totals in 4-6 courses. At the second stage 4 weeks after chemotherapy surgery is performed. The third stage involves 4-6 courses of adjuvant intra-arterial chemotherapy and biotherapy, as at the first stage.
EFFECT: invention allows increasing survival rate and life expectancy of the patients owing to improved respectability of metastases and lower toxicity of complex neoadjuvant and adjuvant intra-arterial chemotherapy and biotherapy.
1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING PATIENTS WITH COLORECTAL CANCER AND WITH RENAL METASTASES | 2005 |
|
RU2297219C2 |
METHOD FOR COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE HEPATIC METASTASES AND IN THE ABSENCE OF MUTATIONS IN THE KRAS AND BRAF GENES | 2021 |
|
RU2764955C1 |
METHOD OF TREATING INOPERABLE PANCREATIC ADENOCARCINOMA WITH LIVER METASTASES | 2019 |
|
RU2706786C1 |
METHOD FOR COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE HEPATIC METASTASES AND IN PRESENCE OF MUTATIONS IN KRAS AND BRAF GENES | 2021 |
|
RU2760174C1 |
METHOD OF THE COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE LIVER METASTASES IN THE PRESENCE OF MUTATIONS IN THE KRAS GENES | 2023 |
|
RU2797847C1 |
METHOD OF COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE LIVER METASTASES | 2023 |
|
RU2813334C1 |
METHOD FOR COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE LIVER METASTASES IN ABSENCE OF MUTATIONS IN KRAS GENES | 2023 |
|
RU2819653C1 |
METHOD OF TREATING INOPERABLE PANCREATIC HEAD ADENOCARCINOMA | 2019 |
|
RU2706341C1 |
METHOD OF TREATING OPERABLE GASTRIC ADENOCARCINOMA | 2019 |
|
RU2706346C1 |
METHOD FOR COMBINED TREATMENT OF COLON CANCER | 2023 |
|
RU2820567C1 |
Authors
Dates
2009-11-10—Published
2007-12-26—Filed